Anna G. Orr

Anna G. Orr

Auto-generated profile, based on publicly available information

Anna G. Orr

Appel Alzheimer’s Disease Research Institute, Weill Cornell Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2022 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
DXDan Xia
Dan Xia
SLSteve Lianoglou
Steve Lianoglou
TSThomas Sandmann
Thomas Sandmann
MCMeredith Calvert
Meredith Calvert
Jung SuhJung Suh
Jung Suh
PSPascal E. Sanchez
Pascal E. Sanchez
Background: Genetic mutations underlying familial Alzheimer’s disease (AD) were identified decades ago, but the field is still in search of transformative therapies for patients. While mouse models based on overexpression of mutated transgenes have yielded key insights in mechanisms of disease, those models are subject to artifacts, including random genetic integration of the transgene, ectopic expression and non-physiological protein levels. The genetic engineering of novel mouse models using knock-in approaches addresses some of those limitations. With mounting evidence of the role played by microglia in AD, high-dimensional approaches to phenotype microglia in those models are critical to refine our understanding of the immune response in the brain. Methods: We engineered a novel App knock-in mouse model (AppSAA) using homologous recombination to introduce three disease-causing coding mutations (Swedish, Arctic and Austrian) to the mouse App gene. Amyloid-β pathology, neurodegeneration, glial responses, brain metabolism and behavioral phenotypes were characterized in heterozygous and homozygous AppSAA mice at different ages in brain and/ or biofluids. Wild type littermate mice were used as experimental controls. We used in situ imaging technologies to define the whole-brain distribution of amyloid plaques and compare it to other AD mouse models and human brain pathology. To further explore the microglial response to AD relevant pathology, we isolated microglia with fibrillar Aβ content from the brain and performed transcriptomics and metabolomics analyses and in vivo brain imaging to measure energy metabolism and microglial response. Finally, we also characterized the mice in various behavioral assays. Results: Leveraging multi-omics approaches, we discovered profound alteration of diverse lipids and metabolites as well as an exacerbated disease-associated transcriptomic response in microglia with high intracellular Aβ content. The AppSAA knock-in mouse model recapitulates key pathological features of AD such as a progressive accumulation of parenchymal amyloid plaques and vascular amyloid deposits, altered astroglial and microglial responses and elevation of CSF markers of neurodegeneration. Those observations were associated with increased TSPO and FDG-PET brain signals and a hyperactivity phenotype as the animals aged. Discussion: Our findings demonstrate that fibrillar Aβ in microglia is associated with lipid dyshomeostasis consistent with lysosomal dysfunction and foam cell phenotypes as well as profound immuno-metabolic perturbations, opening new avenues to further investigate metabolic pathways at play in microglia responding to AD-relevant pathogenesis. The in-depth characterization of pathological hallmarks of AD in this novel and open-access mouse model should serve as a resource for the scientific community to investigate disease-relevant biology.

1 February 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
AOAnna G. Orr
Anna G. Orr
ILIris Lo
Iris Lo
HSHeike Schumacher
Heike Schumacher
KHKaitlyn Ho
Kaitlyn Ho
MGMichael Gill
Michael Gill
LMLennart Mucke
Lennart Mucke

22 March 2024 in Trends in Neurosciences
Verified
Journal Article
Open access
TZTill S. Zimmer
Till S. Zimmer
AOAdam L. Orr
Adam L. Orr
AOAnna G. Orr
Anna G. Orr
Selective vulnerability of specific brain regions and cell populations is a hallmark of neurodegenerative disorders. Mechanisms of selective vulnerability involve neuronal heterogeneity, functional specializations, and differential sensitivities to stressors and pathogenic factors. In this review we discuss the growing body of literature suggesting that, like neurons, astrocytes are heterogeneous and specialized, respond to and integrate diverse inputs, and induce selective effects on brain function. In disease, astrocytes undergo specific, context-dependent changes that promote different pathogenic trajectories and functional outcomes. We propose that astrocytes contribute to selective vulnerability through maladaptive transitions to context-divergent phenotypes that impair specific brain regions and functions. Further studies on the multifaceted roles of astrocytes in disease may provide new therapeutic approaches to enhance resilience against neurodegenerative disorders.

21 April 2023 in Science Advances
Verified
Journal Article
Open access
ALAvital Licht-Murava
Avital Licht-Murava
SMSamantha M. Meadows
Samantha M. Meadows
FPFernando Palaguachi
Fernando Palaguachi
SSSoomin C. Song
Soomin C. Song
SJStephanie Jackvony
Stephanie Jackvony
AOAnna G. Orr
Anna G. Orr
Transactivating response region DNA binding protein 43 (TDP-43) pathology is prevalent in dementia, but the cell type–specific effects of TDP-43 pathology are not clear, and therapeutic strategies to alleviate TDP-43–linked cognitive decline are lacking. We found that patients with Alzheimer’s disease or frontotemporal dementia have aberrant TDP-43 accumulation in hippocampal astrocytes. In mouse models, induction of widespread or hippocampus-targeted accumulation in astrocytic TDP-43 caused progressive memory loss and localized changes in antiviral gene expression. These changes were cell-autonomous and correlated with impaired astrocytic defense against infectious viruses. Among the changes, astrocytes had elevated levels of interferon-inducible chemokines, and neurons had elevated levels of the corresponding chemokine receptor CXCR3 in presynaptic terminals. CXCR3 stimulation altered presynaptic function and promoted neuronal hyperexcitability, akin to the effects of astrocytic TDP-43 dysregulation, and blockade of CXCR3 reduced this activity. Ablation of CXCR3 also prevented TDP-43–linked memory loss. Thus, astrocytic TDP-43 dysfunction contributes to cognitive impairment through aberrant chemokine-mediated astrocytic-neuronal interactions.

24 May 2024 in Cell Reports
Verified
Journal Article
Open access
SMSamantha M. Meadows
Samantha M. Meadows
FPFernando Palaguachi
Fernando Palaguachi
MJMinwoo Wendy Jang
Minwoo Wendy Jang
ALAvital Licht-Murava
Avital Licht-Murava
DBDaniel Barnett
Daniel Barnett
AOAnna G. Orr
Anna G. Orr
Astrocytic receptors influence cognitive function and can promote behavioral deficits in disease. These effects may vary based on variables such as biological sex, but it is not known if the effects of astrocytic receptors are dependent on sex. We leveraged in vivo gene editing and chemogenetics to examine the roles of astrocytic receptors in spatial memory and other processes. We show that reductions in metabotropic glutamate receptor 3 (mGluR3), the main astrocytic glutamate receptor in adults, impair memory in females but enhance memory in males. Similarly, increases in astrocytic mGluR3 levels have sex-dependent effects and enhance memory in females. mGluR3 manipulations also alter spatial search strategies during recall in a sex-specific manner. In addition, acute chemogenetic stimulation of Gi/o-coupled or Gs-coupled receptors in hippocampal astrocytes induces bidirectional and sex-dimorphic effects on memory. Thus, astrocytes are sex-dependent modulators of cognitive function and may promote sex differences in aging and disease.

4 November 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
DBDaniel Barnett
Daniel Barnett
TZTill S. Zimmer
Till S. Zimmer
CBCaroline Booraem
Caroline Booraem
FPFernando Palaguachi
Fernando Palaguachi
SMSamantha M. Meadows
Samantha M. Meadows
AOAdam L. Orr
Adam L. Orr
Neurodegenerative disorders alter mitochondrial functions, including the production of reactive oxygen species (ROS). Mitochondrial complex III (CIII) generates ROS implicated in redox signalling, but its triggers, temporal dynamics, targets and disease relevance are not clear. Here, using site-selective suppressors and genetic manipulations together with live mitochondrial ROS imaging and multiomic profiling, we show that CIII is a dominant source of ROS production in astrocytes exposed to neuropathology-related stimuli. Astrocytic CIII ROS production is dependent on nuclear factor-κB and the mitochondrial sodium-calcium exchanger (NCLX) and causes oxidation of select cysteines within immune- and metabolism-associated proteins linked to neurological disease. CIII ROS amplify metabolomic and pathology-associated transcriptional changes in astrocytes, with STAT3 activity as a major mediator, and facilitate neuronal toxicity. Therapeutic suppression of CIII ROS in mice decreases dementia-linked tauopathy and neuroimmune cascades and extends lifespan. Our findings establish CIII ROS as an important immunometabolic signal transducer and tractable therapeutic target in neurodegenerative disease.